Want to join the conversation?
$HOLX has made a voluntary decision to stop selling CF InPlex, its cystic fibrosis test, due to manufacturing quality issues at a key component supplier that recently resulted in a recall. This will represent a headwind of several million dollars to the US Molecular Diagnostics segment revenue in 2H16, but shouldn't have much effect on margins.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.